Disubstituted pyrazolines and triazolines as factor Xa inhibitors

Abstract

The present application describes disubstituted pyrazolines and triazolines of formulae I and II: or pharmaceutically acceptable salt forms thereof, wherein one of M 1 and M 2 maybe N and D may be a variety of N-containing groups, which are useful as inhibitors of factor Xa.

What is claimed is:  
     
       1. A compound of formula I: 
       or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; 
       M 1  is N;  
       M 2  is CR 1a R 1a ;  
       D is selected from C(═NR 8 )NR 7 R 9 , NHC(═NR 8 )NR 7 R 9 , NR 8 CH(═NR 7 ), C(O)NR 7 R 8 , and CR 8 R 9 NR 7 R 8 ;  
       E is phenyl substituted with 1 R;  
       R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C 1-4  alkyl, OCF 3 , CF 3 , C(O)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ;  
       G is absent;  
       Z is selected from a C 1-4  alkylene, (CH 2 ) r O(CH 2 ) r , (CH 2 ) r NR 3 (CH 2 ) r , (CH 2 ) r C(O)(CH 2 ) r , (CH 2 ) r C(O)O(CH 2 ) r , (CH 2 ) r OC(O)(CH 2 ) r , (CH 2 ) r C(O)NR 3 (CH 2 ) r , (CH 2 ) r NR 3 C(O)(CH 2 ) r , (CH 2 ) r OC(O)O(CH 2 ) r , (CH 2 ) r OC(O)NR 3 (CH 2 ) r , (CH 2 ) r NR 3 C(O)O(CH 2 ) r , (CH 2 ) r NR 3 C(O)NR 3 (CH 2 ) r , (CH 2 ) r S(O) p (CH 2 ) r , (CH 2 ) r SO 2 NR 3 (CH 2 ) r , (CH 2 ) r NR 3 SO 2 (CH 2 ) r , and (CH 2 ) r NR 3 SO 2 NR 3 (CH 2 ) r , provided that Z does not form a N—N, N—O, N—S, NCH 2 N, NCH 2 O, or NCH 2 S bond with group A;  
       R 1a  and R 1b  are, at each occurrence, independently selected from H, —(CH 2 ) r —R 1′ , NHCH 2 R 1″ , OCH 2 R 1″ , SCH 2 R 1″ , NH(CH 2 ) 2 (CH 2 ) t R 1″ , O(CH 2 ) 2 (CH 2 ) t R 1′ , and S(CH 2 ) 2 (CH 2 ) t R 1′ ;  
       R 1c  is selected from H, —(CH 2 ) q —R 1′ , C 1-3  alkyl, C(O)R 2c , (CF 2 ) r CO 2 R 2c , C(O)NR 2 R 2a , C 3-6  carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4 ;  
       R 1′  is selected from H, C 1-3  alkyl, halo, (CF 2 ) r CF 3 , OR 2 , NR 2 R 2a , C(O)R 2c , OC(O)R 2 , (CF 2 ) r CO 2 R 2c , S(O) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 (O)R 2b , NR 2 C(O)NHR 2b , NR 2 C(O) 2 R 2a , OC(O)NR 2b , C(O)NR 2 R 2a , SO 2 NR 2 R 2a , NR 2 SO 2 R 2b , C 3-6  carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4 ;  
       R 1″  is selected from H, C(O)R 2b , C(O)NR 2 R 2a , S(O)R 2b , S(O) 2 R 2b , and SO 2 NR 2 R 2a ;  
       R 2 , at each occurrence, is selected from H, CF 3 , C 1-6  alkyl, benzyl, C 3-6  carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;  
       R 2a , at each occurrence, is selected from H, CF 3 , C 1-6  alkyl, benzyl, C 3-6  carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;  
       R 2b , at each occurrence, is selected from CF 3 , C 1-4  alkoxy, C 1-6  alkyl, benzyl, C 3-6  carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;  
       R 2c , at each occurrence, is selected from CF 3 , OH, C 1-4  alkoxy, C 1-6  alkyl, benzyl, C 3-6  carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;  
        alternatively, R 2  and R 2a  combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b  which comprises from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;  
       R 3 , at each occurrence, is selected from H, C 1-4  alkyl, and phenyl;  
       R 3a , at each occurrence, is selected from H, C 1-4  alkyl, and phenyl;  
       A is a C 3-10  carbocyclic residue substituted with 0-2 R 4 ;  
       B is selected from:  
       X—Y,  
       C 3-10  carbocyclic residue substituted with 0-2 R 4a , pyrrolidinyl substituted with 0-2 R 4a , and imidazolyl substituted with 0-2 R 4a ;  
       X is selected from C 1-4  alkylene and —C(O)—;  
       Y is pyrrolidinyl substituted with 0-2 R 4a ;  
       R 4 , at each occurrence, is selected from ═O, (CH 2 ) r OR 2 , halo, C 1-4  alkyl, —CN, NO 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(O)R 2b , NR 2 C(O)R 2b , C(O)NR 2 R 2a , NR 2 C(O)NR 2 R 2a , C(═NR 2 )NR 2 R 2a , NHC(═NR 2 )NR 2 R 2a , SO 2 NR 2 R 2a , NR 2 SO 2 NR 2 R 2a , NR 2 SO 2 —C 1-4  alkyl, NR 2 SO 2 R 5 , S(O) p R 5 , (CF 2 ) r CF 3 , NCH 2 R 1″ , OCH 2 R 1″ , SCH 2 R 1″ , N(CH 2 ) 2 (CH 2 ) t R 1′ , O(CH 2 ) 2 (CH 2 ) t R 1′ , and S(CH 2 ) 2 (CH 2 ) t R 1′ ,  
        alternatively, one R 4  is a 5-6 membered aromatic heterocycle comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S;  
       R 4a , at each occurrence, is selected from ═O, (CH 2 ) r OR 2 , halo, C 1-4  alkyl, —CN, NO 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(O)R 2b , NR 2 C(O)R 2b , C(O)NR 2 R 2a , NR 2 C(O)NR 2 R 2a , C(═NR 2 )NR 2 R 2a , NHC(═NR 2 )NR 2 R 2a , SO 2 NR 2 R 2a , NR 2 SO 2 NR 2 R 2a , NR 2 SO 2 —C 1-4  alkyl, NR 2 SO 2 R 5 , S(O) p R 5 , and (CF 2 ) r CF 3 ;  
        alternatively, one R 4a  is a 5-6 membered aromatic heterocycle comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R 5 ;  
       R 4b , at each occurrence, is selected from ═O, (CH 2 ) r OR 3 , halo, C 1-4  alkyl, —CN, NO 2 , (CH 2 ) r NR 3 R 3a , (CH 2 ) r C(O)R 3 , NR 3 C(O)R 3a , C(O)NR 3 R 3a , NR 3 C(O)NR 3 R 3a , C(═NR 3 )NR 3 R 3a , NH 3 C(═NR 3 )NR 3 R 3a , SO 2 NR 3 R 3a , NR 3 SO 2 NR 3 R 3a , NR 3 SO 2 —C 1-4  alkyl, NR 3 SO 2 CF 3 , NR 3 SO 2 -phenyl, S(O) p CF 3 , S(O) p —C 1-4  alkyl, S(O) p -phenyl, and (CF 2 ) r CF 3 ;  
       R 5 , at each occurrence, is selected from CF 3 , C 1-6  alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ;  
        R 6 , at each occurrence, is selected from H, OH, (CH 2 ) r OR 2 , halo, C 1-4  alkyl, CN, NO 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(O)R 2b , NR 2 C(O)R 2b , NR 2 C(O)NR 2 R 2a , C(═NH)NH 2 , NHC(═NH)NH 2 , SO 2 NR 2 R 2a , NR 2 SO 2 NR 2 R 2a , and NR 2 SO 2 C 1-4  alkyl;  
       R 7 , at each occurrence, is selected from H, OH, C 1-6  alkyl, C 1-6  alkylcarbonyl, C 1-6  alkoxy, C 1-4  alkoxycarbonyl, (CH 2 ) n -phenyl, C 6-10  aryloxy, C 6-10  aryloxycarbonyl, C 6-10  arylmethylcarbonyl, C 1-4  alkylcarbonyloxy C 1-4  alkoxycarbonyl, C 6-10  arylcarbonyloxy C 1-4  alkoxycarbonyl, C 1-6  alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C 1-4  alkoxycarbonyl;  
       R 8 , at each occurrence, is selected from H, C 1-6  alkyl and (CH 2 ) n -phenyl;  
        alternatively, R 7  and R 8  combine to form a 5 or 6 membered saturated, ring which comprises from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;  
       R 9 , at each occurrence, is selected from H, C 1-6  alkyl and (CH 2 ) n -phenyl;  
       n, at each occurrence, is selected from 0, 1, 2, and 3;  
       p, at each occurrence, is selected from 0, 1, and 2;  
       q, at each occurrence is selected from 1 and 2;  
       r, at each occurrence, is selected from 0, 1, 2, and 3;  
       s is 0; and,  
       t, at each occurrence, is selected from 0 and 1.  
     
     
       2. A compound according to  claim 1 , wherein the compound is of formula Ib:                    
       wherein; 
       Z is selected from a CH 2 O, OCH 2 , CH 2 NH, NHCH 2 , C(O), CH 2 C(O), C(O)CH 2 , NHC(O), C(O)NH, CH 2 S(O) 2 , S(O) 2 (CH 2 ), SO 2 NH, and NHSO 2 , provided that Z does not form a N—N, N—O, NCH 2 N, or NCH 2 O bond with group A; and,  
       A is phenyl substituted with 0-2 R 4 .  
     
     
       3. A compound according to  claim 2 , wherein; 
       Z is selected from a C(O), CH 2 C(O), C(O)CH 2 , NHC(O), C(O)NH, CH 2 S(O) 2 , S(O) 2 (CH 2 ), SO 2 NH, and NHSO 2 , provided that Z does not form a N—N or NCH 2 N bond with group A.  
     
     
       4. A compound according to  claim 3 , wherein; 
       D is selected from C(O)NH 2 , C(═NH)NH 2 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 ; and,  
       R is selected from H, OCH 3 , Cl, and F.  
     
     
       5. A compound according to  claim 4 , wherein; 
       D—E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3-aminocarbonylphenyl, 3-(methylaminomethyl)phenyl, 3-(1-aminoethyl)phenyl, 3-(2-amino-2-propyl)phenyl, 4-chloro-3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro-3-(methylaminomethyl) phenyl, 4-fluoro-3-amidinophenyl, 4-fluoro-3-aminomethylphenyl, and 4-fluoro-3-(methylaminomethyl)phenyl.  
     
     
       6. A compound according to  claim 3 , wherein; 
       Z is C(O)CH 2  and CONH, provided that Z does not form a N—N bond with group A;  
       B is selected from X—Y, phenyl, pyrrolidino, and imidazolyl, and is substituted with 0-1 R 4a ;  
       R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, C 1-4  alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ;  
       R 4a  is selected from C 1-4  alkyl, CF 3 , S(O) p R 5 , SO 2 NR 2 R 2a , and 1-CF 3 -tetrazol-2-yl;  
       R 5 , at each occurrence, is selected from CF 3 , C 1-6  alkyl, phenyl, and benzyl;  
       X is CH 2  or C(O); and,  
       Y is pyrrolidino.  
     
     
       7. A compound according to  claim 6 , wherein; 
       A is selected from the group: phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,  
       B is selected from the group: 2-CF 3 -phenyl, 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 2-(dimelthylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(1′-CF 3 -tetrazol-2-yl)phenyl, 2-methyl-1-imidazolyl, 5-methyl-1-imidazolyl, and 2-methylsulfonyl-1-imidazolyl.  
     
     
       8. A compound according to  claim 3 , wherein; 
       D is selected from C(O)NH 2 , C(═NH)NH 2 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 ; and,  
       R is selected from H, OCH 3 , Cl, and F;  
       Z is C(O)CH 2  and CONH, provided that Z does not form a N—N bond with group A;  
       B is selected from X—Y, phenyl, pyrrolidino, and imidazolyl, and is substituted with 0-1 R 4a ;  
       R 4 , at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, C 1-4  alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ;  
       R 4a  is selected from C 1-4  alkyl, CF 3 , S(O) p R 5 , SO 2 NR 2 R 2a , and 1-CF 3 -tetrazol-2-yl;  
       R 5 , at each occurrence, is selected from CF 3 , C 1-6  alkyl, phenyl, and benzyl;  
       X is CH 2  or C(O); and,  
       Y is pyrrolidino.  
     
     
       9. A compound according to  claim 8  wherein; 
       D—E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3-aminocarbonylphenyl, 3-(methylaminomethyl)phenyl, 3-(1-aminoethyl)phenyl, 3-(2-amino-2-propyl)phenyl, 4-chloro-3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro-3-(methylaminomethyl)phenyl, 4-fluoro-3-amidinophenyl, 4-fluoro-3-aminomethylphenyl, and 4-fluoro-3-(methylaminomethyl)phenyl;  
       A is selected from the group: phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,  
       B is selected from the group: 2-CF 3 -phenyl, 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 2-(dimethylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(1′-CF 3 -tetrazol-2-yl)phenyl, 2-methyl-1-imidazolyl, 5-methyl-1-imidazolyl, and 2-methylsulfonyl-1-imidazolyl.  
     
     
       10. A compound according to  claim 3 , wherein; 
       D is selected from C(═NR 8 )NR 7 R 9 , C(O)NR 7 R 8 , NR 7 R 8 , and CH 2 NR 7 R 8 ;  
       R is selected from H, Cl, F, OR 3 , CH 3 , CH 2 CH 3 , OCF 3 , and CF 3 ;  
       Z is selected from C(O), CH 2 C(O), C(O)CH 2 , NHC(O), and C(O)NH, provided that Z does not form a N—N bond with group A;  
       R 1a  and R 1b  are, at each occurrence, independently selected from H, —(CH 2 ) r —R 1′ , NHCH 2 R 1″ , OCH 2 R 1″ , SCH 2 R 1″ , NH(CH 2 ) 2 (CH 2 ) t R 1′ , O(CH 2 ) 2 (CH 2 ) t R 1′ , and S(CH 2 ) 2 (CH 2 ) t R 1′ ;  
       R 1c  is selected from H, —(CH 2 ) q —R 1′ , C 1-3  alkyl, C(O)R 2c , (CF 2 ) r CO 2 R 2c , and C(O)NR 2 R 2a ;  
       R 1′ , at each occurrence, is selected from H, C 1-3  alkyl, halo, (CF 2 ) r CF 3 , OR 2 , NR 2 R 2a , C(O)R 2c , (CF 2 ) r CO 2 R 2c , S(O) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 C(O)R 2b , NR 2 C(O) 2 R 2b , C(O)NR 2 R 2a , SO 2 NR 2 R 2a , and NR 2 SO 2 R 2b ;  
       R 4 , at each occurrence, is selected from ═O, OH, Cl, F, C 1-4  alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(O)R 2b , NR 2 C(O)R 2b , C(O)NR 2 R 2a , C(═NH)NH 2 , NHC(═NH)NH 2 , SO 2 NR 2 R 2a , NR 2 SO 2 —C 1-4  alkyl, NR 2 SO 2 R 5 , S(O) p R 5 , and (CF 2 ) r CF 3 ;  
       R 4a , at each occurrence, is selected from ═O, OH, Cl, F, C 1-4  alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(O)R 2b , NR 2 C(O)R 2b , C(O)NR 2 R 2a , C(═NH)NH 2 , NHC(═NH)NH 2 , SO 2 NR 2 R 2a , NR 2 SO 2 —C 1-4  alkyl, NR 2 SO 2 R 5 , S(O) p R 5 , (CF 2 ) r CF 3 , and 1-CF 3 -tetrazol-2-yl;  
       R 5 , at each occurrence, is selected from CF 3 , C 1-6  alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ;  
       R 6 , at each occurrence, is selected from H, OH, OR 2 , Cl, F, CH 3 , CN, NO 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(O)R 2b , NR 2 C(O)R 2b , C(═NH)NH 2 , NHC(═NH)NH 2 , and SO 2 NR 2 R 2a ;  
       R 7 , at each occurrence, is selected from H, OH, C 1-6  alkyl, C 1-6  alkylcarbonyl, C 1-6  alkoxy, C 1-4  alkoxycarbonyl, benzyl, C 6-10  aryloxy, C 6-10  aryloxycarbonyl, C 6-10  arylmethylcarbonyl, C 1-4  alkylcarbonyloxy C 1-4  alkoxycarbonyl, C 6-10  arylcarbonyloxy C 1-4  alkoxycarbonyl, C 1-6  alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C 1-4  alkoxycarbonyl;  
       R 8 , at each occurrence, is selected from H, C 1-6  alkyl and benzyl; and  
        alternatively, R 7  and R 8  combine to form a morpholino group; and,  
       R 9 , at each occurrence, is selected from H, C 1-6  alkyl and benzyl.  
     
     
       11. A compound according to  claim 10 , wherein; 
       R is selected from H, Cl, F, OCH 3 , CH 3 , OCF 3 , and CF 3 ;  
       Z is selected from a C(O)CH 2  and C(O)NH, provided that Z does not form a N—N bond with group A;  
       R 1a , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(O) p R 2b , CH 2 S(O) p R 2b , CH 2 NR 2 S(O) 2 R 2b , C(O)R 2c , CH 2 C(O)R 2c , C(O)NR 2 R 2a , and SO 2 NR 2 R 2a ;  
       R 1b  is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(O) p R 2b , CH 2 S(O) p R 2b , CH 2 NR 2 S(O) 2 R 2b , C(O)R 2c , CH 2 C(O)R 2c , C(O)NR 2 R 2a , and SO 2 NR 2 R 2a ;  
       R 1c  is selected from H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 S(O) p R 2b , CH 2 NR 2 S(O) p R 2b , C(O)R 2c , CH 2 C(O)R 2c , and C(O)NR 2 R 2a ;  
       R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl;  
       R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl;  
       R 2b , at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl;  
       R 2c , at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl;  
        alternatively, R 2  and R 2a  combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which comprises from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;  
       R 3 , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl;  
       R 3a , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl;  
       R 4 , at each occurrence, is selected from OH, Cl, F, CH 3 , CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2a , C(O)R 2b , NR 2 C(O)R 2b , C(O)NR 2 R 2a , and CF 3 ;  
       R 4a , at each occurrence, is selected from OH, Cl, F, CH 3 , CH 2 CH 3 , NR 2 R 2a , CH 2 NR 2 R 2a , C(O)R 2b , C(O)NR 2 R 2a , SO 2 NR 2 R 2a , S(O) p R 5 , CF 3 , and 1-CF 3 -tetrazol-2-yl;  
       R 5 , at each occurrence, is selected from CF 3 , C 1-6  alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 1 R 6 ;  
        R 6 , at each occurrence, is selected from H, OH, OCH 3 , Cl, F, CH 3 , CN, NO 2 , NR 2 R 2a , CH 2 NR 2 R 2a , and SO 2 NR 2 R 2a ;  
       R 7 , at each occurrence, is selected from H, OH, C 1-3  alkyl, C 1-3  alkylcarbonyl, C 1-3  alkoxy, C 1-4  alkoxycarbonyl, benzyl, phenoxy, phenoxycarbonyl, benzylcarbonyl, C 1-4  alkylcarbonyloxy C 1-4  alkoxycarbonyl, phenylcarbonyloxy C 1-4  alkoxycarbonyl, C 1-6  alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C 1-4  alkoxycarbonyl;  
       R 8 , at each occurrence, is selected from H, CH 3 , and benzyl; and,  
        alternatively, R 7  and R 8  combine to form a morpholino group;  
       R 9 , at each occurrence, is selected from H, CH 3 , and benzyl.  
     
     
       12. A compound according to  claim 11 , wherein; 
       R 1a , at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(O) p R 2b , C(O)NR 2 R 2a , CH 2 S(O) p R 2b , CH 2 NR 2 S(O) 2 R 2b , C(O)R 2c , CH 2 C(O)R 2c , and SO 2 NR 2 R 2a ;  
       R 1b  is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(O) p R 2b , C(O)NR 2 R 2a , CH 2 S(O) p R 2b , CH 2 NR 2 S(O) 2 R 2b , C(O)R 2b , CH 2 C(O)R 2b , and SO 2 NR 2 R 2a ;  
       R 1c  is selected from H, CH 3 , CH 2 CH 3 , CF 3 , C(O)NR 2 R 2a , CH 2 S(O) p R 2b , CH 2 NR 2 S(O) p R 2b , C(O)R 2b , and CH 2 C(O)R 2b ;  
       R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl;  
       R 2a , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl;  
       R 2b , at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl;  
       R 2c , at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl;  
        alternatively, R 2  and R 2a  combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino;  
       R 4 , at each occurrence, is selected from Cl, F, CH 3 , NR 2 R 2a , and CF 3 ;  
       R 4a , at each occurrence, is selected from Cl, F, CH 3 , SO 2 NR 2 R 2a , S(O) p R 5 , and CF 3 ; and,  
       R 5 , at each occurrence, is selected from CF 3  and CH 3 .  
     
     
       13. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
       14. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
       15. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 2  or a pharmaceutically acceptable salt thereof. 
     
     
       16. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 3  or a pharmaceutically acceptable salt thereof. 
     
     
       17. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 4  or a pharmaceutically acceptable salt thereof. 
     
     
       18. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 5  or a pharmaceutically acceptable salt thereof. 
     
     
       19. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 6  or a pharmaceutically acceptable salt thereof. 
     
     
       20. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 7  or a pharmaceutically acceptable salt thereof. 
     
     
       21. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 8  or a pharmaceutically acceptable salt thereof. 
     
     
       22. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 9  or a pharmaceutically acceptable salt thereof. 
     
     
       23. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 10  or a pharmaceutically acceptable salt thereof. 
     
     
       24. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 11  or a pharmaceutically acceptable salt thereof. 
     
     
       25. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to  claim 12  or a pharmaceutically acceptable salt thereof. 
     
     
       26. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 2  or a pharmaceutically acceptable salt thereof. 
     
     
       27. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 3  or a pharmaceutically acceptable salt thereof. 
     
     
       28. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 4  or a pharmaceutically acceptable salt thereof. 
     
     
       29. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 5  or a pharmaceutically acceptable salt thereof. 
     
     
       30. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 6  or a pharmaceutically acceptable salt thereof. 
     
     
       31. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 7  or a pharmaceutically acceptable salt thereof. 
     
     
       32. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 8  or a pharmaceutically acceptable salt thereof. 
     
     
       33. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 9  or a pharmaceutically acceptable salt thereof. 
     
     
       34. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 10  or a pharmaceutically acceptable salt thereof. 
     
     
       35. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 11  or a pharmaceutically acceptable salt thereof. 
     
     
       36. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to  claim 14  or a pharmaceutically acceptable salt thereof.